Stocks of the Hour: Home Consortium, Telix Pharmaceuticals & Calix

Company News

by Lauren Evans

Home Consortium (ASX:HMC) is rebranding its company name to HMC Capital. The new name is said to reflect the company's growth as a fund manager and ambition to become a more diversified asset manager. Shares are trading 2.1 per cent higher at $6.98.

Telix Pharmaceuticals’ (ASX:TLX) phase three study of investigational kidney cancer, named ZIRCON, has reached its target enrolment of dosing 252 patients. Telix will continue recruiting into the study for another three months. Shares are trading 0.2 per cent higher at $4.66.

Calix (ASX:CXL) has received approval for its crop protection product BOOSTER-Mag, following an initial application in January 2020. The company said the product aims to reduce farmer input costs and produce food more safely and sustainably. Shares are trading 4 per cent higher at $6.50.
 

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.